Please login to the form below
celecoxib
This page shows the latest celecoxib news and features for those working in and with pharma, biotech and healthcare.
Products over pipeline in Pfizer's acquisition targets, hints CEO
Most damaging to Pfizer's top-line this year was the loss of patent protection for big-selling painkiller Celebrex (celecoxib) last December in the US, with competition already being felt
Latest news
-
Pfizer 2014 guidance threatened by Celebrex competition
Several generic pharma companies have been planning to launch copycat versions of Celebrex (celecoxib) in the US on May 30, when the basic patent on the active ingredient of the drug
-
Pfizer sales down but oncology shows promise
There were also gains for anti-inflammatory Celebrex (celecoxib), up 11 per cent to $752m, while fibromyalgia drug Lyrica (pregabalin) cemented its position as Pfizer's biggest-selling product with a
-
Pfizer sales dip as net income surges in Q2
Epilepsy, neuropathic pain and fibromyalgia therapy Lyrica (pregabalin) cemented its position as Pfizer's biggest product with a 10 per cent gain to $1.13bn, while painkiller Celebrex (celecoxib) grew 10
-
GSK fires senior Chinese scientist over data fabrication
to faking dozens of research studies, including trials of Pfizer's Celebrex (celecoxib) and Merck &Co's Vioxx (rofecoxib).
-
Pfizer sues as Celebrex patent is reissued in US
The patent (No. RE44048) covers methods of treating osteoarthritis and other approved conditions with celecoxib, said Pfizer in a statement. ... We are pleased with the reissuance of this patent protecting the invention of using celecoxib to treat
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
Latest appointments
-
Immunocore names CEO
During this time he helped bring several drugs to markets including Celebrex (celecoxib) and Relpax (eletriptan) and to establish the company in India and China.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Director Healthcare PR Communications
-
Salary TBC
- Experienced Editor, London, Medical Communications
-
Competitive package
- Account Manager, Healthcare Advertising
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Associate Medical Director
-
Highly Competitive
-
Scientific Director
-
Highly Competitive Salary &Benefits
-
Account Director - Digital
-
Great salary and benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Associate Medical Director
-
Salary TBC
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Account Director
-
Negotiable
- Account Director – Global Healthcare PR
-
Salary TBC
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Scientific Team Lead
-
Competitive Salary
Subscribe to our email news alerts
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
Quick links
Infographics
